|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
'Cushing's disease of the omentum' has been proposed as an underlying mechanism in the pathogenesis of central obesity and raises the exciting possibility of selective 11beta-HSD1 inhibition as a novel therapy for patients with the metabolic syndrome.
|
12943516 |
2003 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 11beta-HSD-1 -/- mice were found to resist hyperglycamia provoked by obesity or stress.
|
9405715 |
1997 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The changes in intracellular glucocorticoid metabolism in the pathogenesis of obesity indicate the participation of modulation by 11<i>β</i>-HSD1, which may represent a new therapeutic target for the treatment of diseases such as type 2 diabetes, visceral obesity, or atherosclerosis.
|
31214617 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the activity and reaction direction of adipose 11beta-HSD1 is altered under conditions of oxysterol excess, and could impact upon the pathophysiology of obesity and its complications.
|
18755798 |
2008 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
11beta-HSD1 plays a crucial role in the pathogenesis of obesity and controls glucocorticoid actions in inflammation.
|
19088256 |
2009 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, 11beta-HSD1 acts at the interface of inflammation and obesity and represents an efficient integrator and effector of local inflammatory and metabolic state.
|
20045052 |
2010 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transgenic overexpression of 11beta-HSD1 in either adipose tissue or the liver in mice causes components of the metabolic syndrome, while transgenic deletion of 11beta-HSD1 prevents adverse metabolic complications of obesity.
|
17912154 |
2007 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increasing 11beta-HSD1 and leptin mRNA in SC with increasing BMI SDS could suggest that the risk of metabolic consequences of obesity may be established early in life.
|
17060929 |
2007 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic variation in 11beta-HSD1 contributes to enhanced cortisol clearance and compensatory adrenal hyperandrogenism in lean patients with PCOS but may be protective against obesity and some features of the metabolic syndrome.
|
16551740 |
2006 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
At a pre-receptor level, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activates cortisol from cortisone locally within adipose tissue, and inhibition of 11beta-HSD1 in liver and adipose tissue has been proposed as a novel therapy to treat MS by reducing hepatic glucose output and adiposity.
|
18434359 |
2008 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
11beta-HSD1 is implicated in the pathogenesis of metabolic syndrome and its dysregulation has been observed in pregnancy-related complications (pre-eclampsia, intrauterine growth restriction).
|
27018008 |
2017 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
'Cushing's disease of the omentum' has been proposed as an underlying mechanism in the pathogenesis of central obesity and raises the exciting possibility of selective 11beta-HSD1 inhibition as a novel therapy for patients with the metabolic syndrome.
|
12943516 |
2003 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
11Beta-HSD1 in adipose tissue is increased in obesity in both women and men, and may contribute to the associated metabolic syndrome.
|
17712112 |
2007 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
These results strongly support the rationale for inhibiting 17beta-HSD1 in breast cancer therapy to eliminate estrogen activation via the sulfatase pathway while avoiding the deprivation of DHT.
|
20172961 |
2010 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments.
|
29248731 |
2018 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The high activity of estrogen activation provides the basis of 17β-HSD1's implication in estrogen-dependent diseases, such as breast cancer, endometriosis and non-small cell lung carcinomas.
|
27102893 |
2016 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
|
20151319 |
2010 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
This indicates that 17β-HSD1 may be involved in oncogenesis by favoring anti-apoptosis pathway in breast cancer cells and correborates with its previously shown role in increasing breast cancer cell proliferation.
|
27544780 |
2017 |
|
Metabolic Diseases
|
0.050 |
Biomarker
|
group |
BEFREE |
Liver, skeletal muscle, endocrine pancreas, blood vessels and leukocytes express 11beta-HSD1 and their potential role in metabolic disease is discussed.
|
19804814 |
2010 |
|
Metabolic Diseases
|
0.050 |
Biomarker
|
group |
BEFREE |
Here, we review recent evidence pertaining to the anti-inflammatory role of 11beta-HSD1 and describe how inhibition of 11beta-HSD1, as widely proposed for treatment of metabolic disease, may impact upon inflammation.
|
18973788 |
2009 |
|
Metabolic Diseases
|
0.050 |
Biomarker
|
group |
BEFREE |
Trials in humans though will be the ultimate test to determine if inhibition of 11beta-HSD1 offers a new tool in the treatment of metabolic disease.
|
17912154 |
2007 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
Inhibition of 11beta-HSD1 is a promising therapeutic approach in type 2 diabetes.
|
18852329 |
2009 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
Biomarker
|
disease |
BEFREE |
The changes in intracellular glucocorticoid metabolism in the pathogenesis of obesity indicate the participation of modulation by 11<i>β</i>-HSD1, which may represent a new therapeutic target for the treatment of diseases such as type 2 diabetes, visceral obesity, or atherosclerosis.
|
31214617 |
2019 |
|
Fetal Growth Retardation
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
11beta-HSD1 is implicated in the pathogenesis of metabolic syndrome and its dysregulation has been observed in pregnancy-related complications (pre-eclampsia, intrauterine growth restriction).
|
27018008 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Inhibition of human 17β-HSD1 led to xenograft tumor shrinkage.
|
27102893 |
2016 |